|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61K 35/17 | (2006.01) |
| (11) | Number of the document | 2649086 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11846757.0 |
| Date of filing the European patent application | 2011-12-09 | |
| (97) | Date of publication of the European application | 2013-10-16 |
| (45) | Date of publication and mention of the grant of the patent | 2017-07-19 |
| (46) | Date of publication of the claims translation | 2017-11-10 |
| (86) | Number | PCT/US2011/064191 |
| Date | 2011-12-09 |
| (87) | Number | WO 2012/079000 |
| Date | 2012-06-14 |
| (30) | Number | Date | Country code |
| 201161502649 P | 2011-06-29 | US | |
| 421470 P | 2010-12-09 | US |
| (72) |
JUNE, Carl, H., US
LEVINE, Bruce, L., US
PORTER, David, L., US
KALOS, Michael, D., US
MILONE, Michael C., US
|
| (73) |
The Trustees of The University of Pennsylvania,
Center for Technology Transfer 3160 Chestnut Street, Suite 200, Philadelphia PA 19104-6283,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui |
| USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER |
| Payment date | Validity (years) | Amount | |
| 2024-12-03 | 14 | 289.00 EUR |
| 2025-12-09 |